These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 9853191)
1. The effects of norepinephrine on myocardial biology: implications for the therapy of heart failure. Colucci WS Clin Cardiol; 1998 Dec; 21(12 Suppl 1):I20-4. PubMed ID: 9853191 [TBL] [Abstract][Full Text] [Related]
2. Adrenergic overload and apoptosis in heart failure: implications for therapy. Colucci WS; Sawyer DB; Singh K; Communal C J Card Fail; 2000 Jun; 6(2 Suppl 1):1-7. PubMed ID: 10908092 [TBL] [Abstract][Full Text] [Related]
3. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988 [TBL] [Abstract][Full Text] [Related]
4. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Sabbah HN Heart Fail Rev; 2004 Apr; 9(2):91-7. PubMed ID: 15516856 [TBL] [Abstract][Full Text] [Related]
12. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Newton GE; Parker JD Circulation; 1996 Aug; 94(3):353-8. PubMed ID: 8759076 [TBL] [Abstract][Full Text] [Related]
13. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure. Karam S; Margaria JP; Bourcier A; Mika D; Varin A; Bedioune I; Lindner M; Bouadjel K; Dessillons M; Gaudin F; Lefebvre F; Mateo P; Lechène P; Gomez S; Domergue V; Robert P; Coquard C; Algalarrondo V; Samuel JL; Michel JB; Charpentier F; Ghigo A; Hirsch E; Fischmeister R; Leroy J; Vandecasteele G Circulation; 2020 Jul; 142(2):161-174. PubMed ID: 32264695 [TBL] [Abstract][Full Text] [Related]
14. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Fowler MB; Bristow MR Am J Cardiol; 1985 Apr; 55(10):120D-124D. PubMed ID: 2859789 [TBL] [Abstract][Full Text] [Related]
15. Sympathetic activation and the role of beta-blockers in chronic heart failure. Krum H Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514 [TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular mechanisms of myocardial failure. Colucci WS Am J Cardiol; 1997 Dec; 80(11A):15L-25L. PubMed ID: 9412539 [TBL] [Abstract][Full Text] [Related]
17. [The effects of combined beta(1) adrenergic receptor antagonist and beta(2) adrenergic receptor agonist therapy on cardiac function and myocardial apoptosis in heart failure rats]. Li WM; Gan RT; Wang X; Wu S; Shen JX; Xiu CH Zhonghua Xin Xue Guan Bing Za Zhi; 2007 Jul; 35(7):615-9. PubMed ID: 17961425 [TBL] [Abstract][Full Text] [Related]
18. Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. Song YH; Cai H; Gu N; Qian CF; Cao SP; Zhao ZM J Pharm Pharmacol; 2011 Apr; 63(4):541-9. PubMed ID: 21401606 [TBL] [Abstract][Full Text] [Related]
19. Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers. Eichhorn EJ Cardiol Clin; 1998 Nov; 16(4):711-25, ix. PubMed ID: 9891599 [TBL] [Abstract][Full Text] [Related]
20. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Kobayashi M; Machida N; Mitsuishi M; Yamane Y Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]